cancer
transplant
patient
higher
risk
develop
sever
even
fatal
respiratori
diseas
especi
may
treat
immunesuppress
immunestimul
drug
review
focus
effect
drug
host
immun
sinc
outbreak
sever
acut
respiratori
syndrom
sar
coronaviru
start
china
decemb
increas
evid
exist
comorbid
older
age
compromis
immun
system
higher
risk
develop
sever
even
fatal
respiratori
diseas
cancer
transplant
patient
also
consid
risk
group
especi
may
treat
immunesuppress
immunestimul
drug
current
review
focus
effect
immunesuppress
immunestimul
drug
host
immun
report
short
introduct
drug
follow
summari
result
identifi
studi
rel
drug
hypothesis
drug
select
like
categoris
one
two
group
may
harm
patient
put
risk
increas
morbiditymort
associ
infect
may
use
treat
immunopatholog
associ
sever
persist
viral
infect
clinic
impact
review
thu
twofold
aim
identifi
drug
clinician
think
take
patient
protect
increas
harm
also
drug
could
potenti
benefici
fight
diseas
review
cover
inform
avail
today
pandem
progress
opportun
respons
collect
prospect
data
use
establish
randomis
control
trial
involv
drug
interest
cohortbas
translat
studi
cytotox
chemotherapi
lowdos
steroid
nonsteroid
antiinflammatori
drug
nsaid
tumour
necrosi
factor
tnf
blocker
blockad
janu
kinas
jak
inhibitor
blockad
mycophenol
tacrolimu
search
conduct
use
ovid
medlin
total
studi
includ
review
differ
type
immunesuppress
immunestimul
drug
group
tabl
show
search
term
number
studi
includ
review
lowdos
steroid
nsaid
coronaviru
covid
betacoronaviru
merscov
sarscov
antiinflammatori
ibuprofen
isobutylphenylpropion
acid
cortison
nonsteroid
antiinflammatori
tnf
blocker
coronaviru
covid
betacoronaviru
merscov
sarscov
tnf
blocker
antitnf
therapi
inhibitor
infliximab
etanercept
certolizumab
golimumab
adalimumab
blockad
two
differ
search
strategi
explor
due
number
agent
block
coronaviru
covid
betacoronaviru
merscov
sarscov
therapi
receptor
antibodi
therapi
interlukin
blockag
blockag
il
blockag
blockag
tocilizumab
siltuximab
sylvant
sarilumab
olokizumab
elsilimomab
sirukumab
cnto
clazakizumab
olokizumab
sarilumab
sirukumab
coronaviru
covid
betacoronaviru
merscov
sarscov
interlukin
therapi
blockag
tocilizumab
siltuximab
coronaviru
covid
betacoronaviru
merscov
sarscov
monoclon
antibodi
rituximab
truxima
zevalin
ruxienc
rituxan
arzerra
gazyva
studi
investig
nonsteroid
antiinflammatori
drug
one
look
indomethacin
studi
suggest
indomethacin
exhibit
potent
antivir
activ
canin
coronaviru
dramat
inhibit
viru
replic
protect
host
cell
virusinduc
damag
activ
also
observ
human
sarscov
concentr
dose
mgkg
gener
appear
posit
result
use
corticosteroid
viral
infect
sarscov
corticosteroid
wide
use
sarscov
outbreak
due
known
abil
modul
varieti
involv
cytokin
includ
variou
studi
human
note
corticosteroid
appear
effect
reduc
immunopatholog
damag
concern
centr
around
promot
viral
rebound
associ
advers
event
includ
acut
respiratori
distress
syndrom
one
laboratori
studi
treat
porcin
respiratori
coronaviru
infect
pig
dexamethason
suggest
one
two
dose
corticosteroid
acut
phase
infect
may
effect
allevi
earli
proinflammatori
respons
prolong
administr
may
play
role
enhanc
viral
replic
separ
chines
studi
separ
sarscov
patient
treatment
group
identifi
earli
highdos
steroid
combin
quinolon
produc
best
patient
outcom
nevertheless
one
review
state
current
recommend
corticosteroid
viral
diseas
dengu
glucocorticoidmedi
stimul
hypothalamicpituitaryadren
axi
also
drive
lymphocytopenia
may
promot
exagger
proinflammatori
respons
eventu
caus
worsen
pathogen
condit
current
literatur
give
conclus
evid
use
nsaid
treatment
patient
though
appear
evid
corticosteroid
may
benefici
treatment
sarscov
howev
import
note
specif
tnf
famili
receptor
cytokin
larg
often
target
drug
one
exampl
tnfa
inhibitor
act
supress
physiolog
respons
tnfa
tnfa
proinflammatori
cytokin
involv
autoimmun
immunemedi
disord
rheumatoid
arthriti
ankylos
spondyl
inflammatori
bowel
diseas
psoriasi
hidraden
suppurativa
refractori
asthma
inhibitor
tnfa
may
use
treatment
inhibit
tnfa
achiev
monoclon
antibodi
infliximab
remicad
adalimumab
humira
certolizumab
pegol
cimzia
golimumab
simponi
receptor
fusion
protein
etanercept
enbrel
total
three
studi
identifi
two
deem
suitabl
inclus
supplementari
tabl
first
studi
research
letter
suggest
tnfa
implic
sever
immunebas
pulmonari
injuri
caus
sar
coronaviru
suggest
tnfa
inhibitor
could
potenti
treatment
acut
respiratori
diseas
syndrom
caus
coronaviru
second
studi
utilis
piglet
assess
efficaci
antitnfa
therapi
endotoxin
respiratori
diseas
observ
tnfa
blockad
associ
decreas
diseas
sever
current
evid
indic
tnfa
blockad
harm
patient
context
promptli
transient
produc
respons
infect
tissu
injuri
contribut
host
defenc
stimul
acut
phase
respons
hematopoiesi
immun
reaction
although
express
strictli
control
transcript
posttranscript
mechan
dysregul
continu
synthesi
play
patholog
effect
chronic
inflamm
autoimmun
reason
tocilizumab
human
receptor
antibodi
develop
approv
anti
drug
siltuximab
sylvant
sarilumab
sever
agent
clinic
trial
olokizumab
elsilimomab
sirukumab
cnto
clazakizumab
olokizumab
sarilumab
sirukumab
total
studi
identifi
second
search
strategi
suitabl
inclus
supplementari
tabl
first
search
strategi
found
hit
induc
proinflammatori
gener
secret
cytokin
includ
via
toll
like
receptor
tlr
caus
product
activ
matur
mediat
lung
inflamm
fever
fibrosi
antiinflammatori
cytokin
could
potenti
provid
relief
system
inflamm
fever
occur
infect
cytokin
profil
patient
diagnos
sar
show
mark
elev
thelper
lymphocyt
type
cytokin
interferongamma
inflammatori
cytokin
least
two
week
diseas
onset
children
howev
present
much
milder
cytokin
chemokin
storm
high
level
acut
stage
associ
lung
lesion
found
sar
patient
activ
viral
nucleocapsid
sarscov
n
protein
induct
inflammatori
cytokin
dysregul
cytokin
signal
observ
patient
sar
comparison
respiratori
virus
includ
respiratori
syncyti
viru
rsv
influenza
viru
fluav
human
parainfluenza
viru
type
sarscov
rsv
induc
high
level
rant
compar
fluav
nprotein
sarscov
induc
pulmonari
inflammatori
reaction
acut
lung
injuri
relat
increas
imbal
proinflammatori
antiinflammatori
cytokin
glucocorticoid
could
effect
allevi
pulmonari
inflammatori
reaction
induc
nprotein
sarscov
sarscov
product
infect
human
macrophag
mphi
dentrit
cell
dc
howev
modul
massiv
releas
compromis
endocyt
capac
eg
antigen
captur
captur
mphi
significantli
compromis
chang
plasma
helper
th
cell
cytokin
inflammatori
cytokin
chemokin
patient
diagnos
sar
assess
elev
cytokin
inflammatori
cytokin
chemokin
confirm
activ
cellmedi
immun
hyperinn
inflammatori
respons
sar
accumul
monocytesmacrophag
neutrophil
blood
measur
seem
use
diagnos
sever
case
find
suggest
ddimer
level
use
estim
sever
optimum
critic
point
group
pgml
upper
limit
sever
pneumonia
increas
express
serum
expect
predict
sever
pneumonia
prognosi
patient
serum
level
significantli
elev
merscov
patient
develop
sever
diseas
new
lethal
anim
model
characteris
sarscov
strain
nine
mutat
increas
level
mice
high
express
correl
mortal
sar
vaccin
test
murin
sar
model
high
level
day
sarscov
infect
close
link
viru
replic
diseas
sever
key
sarscovinduc
epitheli
cytokin
capabl
inhibit
tcellprim
abil
dendrit
cell
cellular
element
host
innat
defens
respiratori
infect
lead
exacerb
inflammatori
cascad
sever
tissu
damag
sar
patient
patient
diagnosi
sarsassoci
coronaviru
infect
signific
differ
peak
level
patient
without
acut
respiratori
distress
syndrom
howev
crp
associ
wors
outcom
might
use
prognost
marker
sar
ifngamma
tgfbeta
mig
highli
elev
acut
phase
sera
taiwan
sar
patient
mig
significantli
higher
death
group
surviv
group
suggest
interferongammarel
cytokin
storm
induc
post
sar
coronaviru
infect
eight
patient
sar
treat
ribavirin
effect
reduc
sar
coronaviru
load
three
eight
elev
level
interleukin
il
subsequ
peak
viral
load
found
eight
six
case
cytokin
profil
perform
serum
healthi
donor
patient
sar
patient
sever
sar
patient
sar
convalesc
concentr
significantli
elev
sever
sar
patient
concentr
similar
convalesc
patient
control
subject
suggest
associ
sar
sever
author
studi
set
studi
inflammatori
cytokin
profil
children
sar
found
plasma
concentr
key
proinflammatori
cytokin
includ
substanti
increas
patient
throughout
cours
ill
author
state
cytokin
result
cast
doubt
liber
use
corticosteroid
paediatr
sar
patient
regul
class
switch
mediat
proand
antiinflammatori
respons
viral
antigen
stimuli
ebola
sarscov
dengu
infect
human
therefor
consid
potenti
target
molecul
novel
antivir
drug
discoveri
infect
sarscov
sarscov
ssrna
new
therapeut
target
given
capac
caus
acut
lung
injuri
mice
high
mortal
rate
vivo
experi
suggest
sarscov
specif
gurich
ssrna
play
import
role
cytokin
storm
associ
dysregul
innat
immun
mapk
potenti
therapeut
target
coronaviru
infecti
bronchiti
viru
given
capabl
reduc
product
excess
amount
infect
cell
pretreat
primari
cultur
human
nasal
tracheal
epitheli
cell
glycopyrronium
formoterol
decreas
viral
rna
level
andor
titer
express
infectioninduc
product
cytokin
includ
ifnbeta
treatment
cell
inhibitor
decreas
viral
titer
pretreat
cell
combin
three
drug
glycopyrronium
formoterol
budesonid
exert
addit
inhibitori
effect
viral
titer
cytokin
product
suggest
pathogenesi
sarscov
mediat
disproport
immun
respons
abil
viru
circumv
innat
immun
infect
also
observ
induc
proinflammatori
cytokin
gener
secret
cytokin
dysregul
local
inflammatori
respons
suggest
partial
respons
devast
acut
respiratori
distress
syndrom
moreov
observ
induc
high
level
least
week
diseas
onset
children
present
lower
level
cytokin
product
suggest
potenti
prognost
marker
diseas
sever
differ
molecul
relat
pathway
suggest
potenti
therapeut
target
sarscov
ssrna
mapk
current
scientif
evid
benefici
impact
inhibitor
modul
infect
understand
role
reduct
forthcom
pandem
progress
clinic
data
becom
avail
vitro
treatment
glycopyrronium
formoterol
budesonid
exert
addit
inhibitori
effect
viral
titer
cytokin
product
human
nasal
tracheal
epitheli
cell
jak
inhibitor
work
inhibit
activ
one
jak
famili
enzym
includ
jak
interact
signal
transduc
activ
transcript
protein
stat
jakstat
pathway
central
cellular
respons
exogen
signal
immun
system
jak
famili
enzym
respons
signal
transduct
jak
inhibitor
play
major
role
inhibit
block
cytokin
releas
contribut
growth
malign
cell
cancer
jak
inhibitor
use
treatment
cancer
inflammatori
diseas
rheumatoid
arthriti
review
focus
jakstat
pathway
manipul
reduc
viral
entri
inflamm
patient
coronaviru
main
target
review
highlight
baricitinib
jak
inhibitor
endoplasm
reticulum
stress
sensor
lead
increas
express
neg
regul
jakstat
combin
therapi
use
tylophorinebas
compound
inhibitor
fifteen
studi
yield
search
deem
suitabl
inclus
supplementari
tabl
baricitinib
olumi
jak
inhibitor
approv
european
medicin
agenc
februari
treatment
moderatetosever
activ
rheumatoid
arthriti
adult
inadequ
respons
one
diseasemodifi
antirheumat
drug
one
studi
suggest
use
baricitinib
reduc
viral
entri
inflamm
caus
virus
enter
cell
receptormedi
endocytosi
cellsurfac
protein
express
cell
kidney
blood
vessel
heart
alveola
type
cell
pulmonari
epithelia
may
receptor
use
infect
lung
cell
author
richardson
et
al
suggest
inhibit
adaptor
associ
protein
kinas
receptor
promot
endocytosi
involv
baricitinib
may
reduc
viral
entri
inflamm
patient
inositolrequir
transmembran
kinaseendoribonucleas
endoplasm
reticulum
stress
sensor
lead
increas
express
neg
regul
jakstat
suppressor
cytokin
signal
soc
therefor
may
novel
target
coronaviru
infect
requir
explor
tylophorinebas
compound
isol
plant
exert
potent
anticoronavir
activ
sarscov
merscov
nuclear
factor
kappalightchainenhanc
activ
b
cell
activ
common
proinflammatori
respons
host
cell
viral
infect
follow
vitro
analysi
yang
et
al
suggest
use
combin
therapi
sarscov
merscov
wherein
tylophorin
compound
known
target
transmiss
gastroenter
viru
inhibitor
synergis
block
altern
domin
activ
mediat
therefor
combin
treatment
inhibit
coronaviru
per
se
eg
viral
genom
replic
block
cellular
activ
coronavirus
promis
approach
develop
anticoronavir
current
studi
suggest
although
potenti
target
jakstat
pathway
manipul
treatment
coronavirus
earli
stage
requir
vitro
vivo
studi
confirm
therapeut
effect
proinflammatori
cytokin
import
mediat
local
system
inflamm
excess
releas
viral
infect
caus
lung
tissu
inflamm
fever
fibrosi
suppress
found
effect
mani
inflammatori
diseas
includ
rheumatoid
arthriti
well
establish
overexpress
hallmark
sarscov
infect
probabl
activ
transcript
factor
nuclear
factor
activ
protein
activ
factor
specif
viru
thought
bind
tlr
activ
format
activ
inflammasom
inflammasom
activ
import
regul
cell
innat
adapt
immun
system
pave
way
specif
immun
respons
part
inflammasom
activ
subsequ
produc
mediat
inflamm
lung
fever
fibrosi
thu
caus
respiratori
complic
infect
host
total
studi
identifi
search
deem
suitabl
inclus
supplementari
tabl
mani
studi
vitro
studi
repeatedli
demonstr
increas
level
patient
infect
coronaviru
one
studi
investig
level
variou
inflammatori
cytokin
patient
china
compar
level
gener
sever
critic
ill
group
author
report
signific
differ
level
three
group
patient
anoth
studi
involv
consecut
sar
patient
admit
hong
kong
hospit
identifi
significantli
elev
level
within
first
day
follow
onset
infect
patient
sever
diseas
treat
puls
methylprednisolon
level
return
normal
day
seven
patient
less
sever
diseas
receiv
dosag
corticosteroid
cytokin
level
return
normal
rang
level
time
period
chines
studi
also
identifi
reduc
level
follow
administr
corticosteroidssuggest
inhibit
proinflammatori
cytokin
may
benefici
treatment
strategi
treatment
sar
third
studi
measur
serum
cytokin
level
four
patient
group
includ
control
patient
sar
patient
sever
sar
convalesc
sar
patient
suggest
longer
term
treatment
period
day
lowdos
steroid
alter
serum
cytokin
level
includ
one
rat
model
show
promis
result
receptor
antagonist
reduc
chemokin
express
infect
anim
howev
result
generalis
human
unfortun
one
studi
author
state
demonstr
first
time
inflamm
coronaviru
may
inhibit
antiinflammatori
cytokin
belong
famili
avail
abstract
therefor
evid
inform
back
claim
avail
overal
review
demonstr
although
evid
elev
patient
infect
coronaviru
present
evid
establish
role
blocker
treatment
human
literatur
howev
suggest
potenti
role
lowdos
corticosteroid
reduc
level
proinflammatori
marker
elev
part
immun
respons
may
role
sever
lung
damag
associ
human
coronavirus
mycophenol
mofetil
deriv
mycophenol
acid
mpa
immun
suppress
antineoplast
antivir
mediat
accord
british
nation
formulari
mycophenol
mofetil
use
prophylaxi
acut
reject
renal
transplant
usual
use
combin
corticosteroid
ciclosporin
almost
studi
investig
mpa
potenti
therapi
merscov
due
antivir
properti
six
select
studi
vitro
studi
two
vivo
one
clinic
exampl
four
review
therefor
overlap
result
supplementari
tabl
gener
vitro
studi
look
posit
mpa
target
papain
like
proteas
merscov
sarscov
studi
found
mpa
show
strong
inhibit
viru
low
mpa
use
combin
interferonbeta
ifnb
one
studi
appli
regim
marmoset
exhibit
sever
diseas
resembl
human
mer
report
high
viral
load
sever
even
fatal
diseas
author
studi
state
mpa
like
caus
harm
benefit
mer
patient
accord
review
mo
fisher
mpa
monotherapi
test
clinic
set
treatment
merscov
al
ghamdi
et
al
present
exampl
eight
patient
treat
mpa
merscov
seven
combin
eight
patient
surviv
howev
review
mo
fisher
state
group
patient
lower
acut
physiolog
chronic
health
evalu
ii
score
compar
other
cohort
receiv
varieti
antivir
agent
includ
ribavirin
ifna
steroid
antibiot
therefor
result
must
interpret
caution
whilst
vitro
studi
show
promis
result
mpa
mer
vivo
studi
suggest
use
like
caus
harm
benefit
henc
like
use
coronaviru
infect
clinic
studi
small
confirm
deni
benefici
use
merscov
patient
tacroliumu
also
known
fujimycin
envarsu
immunosuppress
drug
mainli
administ
allogen
organ
transplant
lower
risk
organ
reject
mechan
action
focuss
inhibit
calcineurin
involv
product
cytokin
promot
develop
prolifer
cell
form
vital
compon
human
adapt
immun
respons
total
studi
identifi
search
term
three
deem
suitabl
inclus
supplementari
tabl
overal
literatur
appear
suggest
potenti
role
tacrolimu
treatment
human
coronavirus
case
studi
two
renal
transplant
recipi
test
posit
mer
cov
patient
treat
immunosuppress
regimen
tacrolimu
underw
full
recoveri
whilst
patient
treatment
regimen
succumb
infect
patient
eventu
made
full
recoveri
also
treat
antibacteri
therapi
reduc
dose
mycophenol
mofetil
therefor
possibl
conclud
patient
recoveri
due
tacrolimu
two
includ
studi
laboratori
studi
involv
cell
line
cultur
first
investig
pathway
coronaviru
viral
replic
potenti
antivir
therapeut
target
genomewid
sarscov
yeasttwohybrid
interact
screen
human
cdna
librari
identifi
protein
interact
partner
sarscov
nonstructur
protein
subsequ
author
investig
whether
tacrolimu
inhibit
viral
replic
human
coronavirus
verofm
cell
infect
sarscov
human
coronavirus
treat
result
show
effect
inhibit
viral
replic
sarscov
nontox
lowmicromolar
concentr
reduct
viral
titer
undetect
level
second
studi
confirm
inhibit
use
novel
nonimmunosuppress
deriv
context
lowmicromolar
noncytotox
concentr
cell
cultur
overal
small
amount
literatur
avail
suggest
potenti
role
tacrolimu
potent
antivir
treatment
human
coronavirus
import
note
howev
novel
diseas
may
differ
aetiolog
mechanist
action
compar
exist
strain
date
immunosuppress
drug
deriv
test
human
studi
warrant
clinic
set
laboratori
studi
identifi
inclus
studi
identifi
inclus
rapidli
progress
pandem
led
challeng
decisionmak
treatment
critic
unwel
patient
novel
viral
infect
parallel
doctor
across
multipl
specialti
make
clinic
decis
appropri
continu
treatment
patient
chronic
ill
requir
immunesuppress
medic
systemat
review
look
provid
guidanc
current
avail
literatur
pandem
progress
collect
effort
captur
data
prospect
trial
requir
sponsor
random
control
trial
recruit
patient
random
receiv
immun
modulatori
drug
may
affect
collect
data
diseas
outcom
consid
interim
analysi
potenti
advantag
disadvantag
associ
use
one
medic
lowdos
prednisolon
tacrolimu
therapi
may
benefici
impact
cours
observ
requir
valid
mycophenol
mofetil
pictur
less
clear
conflict
data
preclin
studi
definit
evid
specif
cytotox
drug
lowdos
methotrex
autoimmun
diseas
nsaid
jak
kinas
inhibitor
antitnfa
biolog
agent
contraind
evid
peak
level
associ
sever
pulmonari
complic
ongo
studi
blockad
pathway
ration
hope
inform
practic
pandem
progress
would
like
thank
variou
funder
guy
st
thoma
chariti
cancer
research
uk
cruk
king
health
partner
centr
author
conflict
interest
declar
loss
pulmonari
function
suggest
associ
acut
lung
injuri
reduct
function
caus
dysfunct
reninangiotensin
system
enhanc
inflamm
vascular
permeabl
lung
injuri
suggest
sarscov
infect
read
articl
follow
articl
patient
hypertens
diabet
mellitu
increas
risk
infect
greec
express
substanti
increas
patient
type
type
diabet
treat
ace
inhibitor
angiotensin
ii
typei
receptor
blocker
arb
hypertens
also
treat
ace
inhibitor
arb
result
upregul
increas
thiazolidinedion
ibuprofen
data
suggest
express
increas
diabet
treatment
ace
inhibitor
arb
increas
express
review
articl
aim
look
multipl
diseas
caus
variou
virus
includ
dengu
ebola
sarscov
state
ribavirin
antivir
frequent
use
drug
combat
sarscov
administ
togeth
corticosteroid
although
immunosuppress
corticosteroid
drug
commonli
use
attempt
reduc
fatal
rate
result
clinic
trial
suffici
satisfactori
approv
effect
class
therapeut
glucocorticoidmedi
stimul
hypothalamicpituitaryadren
axi
also
drive
lymphocytopenia
may
promot
exagger
proinflammatori
respons
eventu
caus
worsen
pathogen
condit
pleas
note
specif
refer
viral
diseas
mention
manag
coronaviru
infect
particular
refer
sar
result
also
suggest
dexamethason
induc
reduct
might
play
role
delay
onset
lung
lesion
increas
later
infect
stage
may
contribut
sever
lung
lesion
mimick
delay
onset
diseas
sever
seen
sar
patient
treat
corticosteroid
indomethacin
potent
antivir
activ
sar
coronaviru
indomethacin
common
nsaid
report
describ
indomethacin
unexpectedli
found
possess
potent
antivir
activ
canin
coronaviru
dramat
inhibit
viru
replic
protect
host
cell
virusinduc
damag
activ
also
observ
vivo
human
sarscov
oral
administr
concentr
found
effect
studi
pulmonari
inflammatori
reaction
induc
nprotein
sarscov
rat
model
effect
glucocorticoid
report
benefici
treatment
noninfecti
idiopath
pneumonia
syndrom
follow
stemcel
transplant
pulmonari
syndrom
resembl
sar
pneumonia
respect
sar
coronaviru
inde
lead
massiv
releas
rom
alveolar
macrophag
earli
inhibit
might
abl
prevent
immun
activ
therefor
reduc
pulmonari
injuri
patient
compar
use
corticosteroid
use
biolog
tnf
inhibitor
includ
etanercept
potenti
specif
effect
method
amelior
sever
alveolar
damag
occur
follow
infect
agent
antitnf
alpha
therapi
amelior
diseas
model
acut
virusendotoxin
mediat
respiratori
diseas
pig
copd
bronchial
asthma
exacerb
induc
viral
infect
decreas
product
cell
pretreat
glycopyrronium
formoterol
budesonid
well
increas
inhibitori
effect
gfb
observ
present
studi
may
associ
inhibitori
effect
drug
copd
bronchial
asthma
exacerb
china
patient
admit
isol
ward
tongji
hospit
mild
case
sever
case
critic
case
express
level
inflammatori
cytokin
marker
serum
group
detect
statist
signific
differ
express
level
receptor
serum
three
group
p
among
critic
group
higher
sever
group
sever
group
higher
mild
group
howev
statist
signific
differ
serum
level
tumor
necrosi
factoralpha
tnfalpha
hscrp
lymphocyt
count
ldh
among
three
group
p
sever
acut
respiratori
syndrom
clinic
laboratori
manifest
year
rang
consecut
day
upon
hospit
admiss
day
diseas
onset
cytokin
profil
show
mark
elev
thelper
lymphocyt
type
cytokin
inflammatori
cytokin
least
two
week
diseas
onset
signific
increas
inflammatori
cytokin
antiinflammatori
cytokin
cytokin
thelper
lymphocyt
type
cytokin
also
perform
serial
studi
plasma
cytokin
chemokin
profil
children
sar
boy
girl
age
year
found
patient
much
milder
cytokin
chemokin
storm
render
use
corticosteroid
controversi
unjustifi
interleukin
act
mediat
proand
antiinflammatori
reactiv
initi
transand
classicalsignal
might
relat
cytokin
storm
trigger
excess
proinflammatori
respons
ebola
sarscov
dengu
infect
human
futur
antivir
thu
aim
target
mechan
regul
switch
transand
classicalsign
tumour
necrosi
convert
enzym
could
master
molecul
involv
regul
class
switch
control
proand
antiinflammatori
respons
viral
antigen
stimuli
consid
potenti
target
molecul
novel
antivir
drug
discoveri
would
regul
host
reactiv
infect
therebi
limit
prevent
fatal
outcom
extraordinari
gurich
singlestrand
rna
identifi
sar
coronaviru
contribut
excess
innat
immun
respons
identifi
set
sarscov
specif
gurich
ssrna
fragment
highdens
distribut
genom
vitro
experi
result
show
repres
sarscov
ssrna
power
immunostimulatori
activ
induc
consider
level
proinflammatori
cytokin
tnfa
releas
via
almost
higher
strong
stimulatori
found
previous
viru
moreov
sarscov
ssrna
abl
caus
acut
lung
injuri
mice
high
mortal
rate
vivo
experi
suggest
sarscov
specif
gurich
ssrna
play
import
role
cytokin
storm
associ
dysregul
innat
immun
could
open
new
therapeut
strategi
new
strain
sarscov
strain
characteris
highli
lethal
balbc
mice
nine
mutat
affect
amino
acid
residu
strain
increas
rant
mice
high
express
correl
mortal
neutralis
antibodi
sever
acut
respiratori
syndrom
coronaviru
spike
highli
effect
protect
mice
murin
sar
model
efficaci
three
sar
vaccin
candid
test
murin
sar
model
utilis
lowvirul
pp
sarscov
coinfect
vaccin
mice
protect
sever
respiratori
diseas
high
level
day
sarscov
infect
close
link
viru
replic
diseas
sever
suggest
import
cytokin
lung
pathogen
sarscov
infect
sever
acut
respiratori
syndrom
coronavirusinduc
lung
epitheli
cytokin
exacerb
sar
pathogenesi
modul
intrins
function
monocytederiv
macrophag
dendrit
cell
includ
studi
link
viral
load
ribavirin
proinflammatori
cytokin
clinic
progress
ribavirin
effect
reduc
sar
coronaviru
load
probabl
case
studi
elev
level
interleukin
il
subsequ
peak
viral
load
found
case
respect
analysi
serum
cytokin
patient
sever
acut
respiratori
syndrom
author
studi
set
studi
inflammatori
cytokin
profil
children
sar
found
plasma
concentr
key
proinflammatori
cytokin
includ
substanti
increas
patient
throughout
cours
ill
author
state
cytokin
result
cast
doubt
liber
use
corticosteroid
paediatr
sar
patient
host
immunolog
respons
seem
sever
initi
anticip
author
provid
evid
sarscov
protein
activ
inflammasom
lipopolysaccharideprim
macrophag
ion
channel
activ
protein
essenti
secret
macrophag
obtain
studi
femal
mice
note
plpro
papainlik
proteas
merscov
sarscov
act
potenti
antivir
target
drug
multipl
inhibit
assay
also
support
kinet
mechan
disulfiram
togeth
andor
mpa
synergist
inhibit
merscov
plpro
due
competit
mode
inhibit
sarscov
plpro
synergist
inhibit
merscov
plpro
disulfiram
mycophenol
acid
impli
potenti
combin
treatment
use
three
clinic
avail
drug
combin
mycophenol
acid
interferon
beta
show
synergist
activ
merscov
vero
cell
desir
pharmacokinet
mycophenol
acid
compar
ribavirin
warrant
evalu
although
potenti
inhibitori
effect
immun
system
therefor
neutralis
antibodi
product
fulli
assess
anim
model
use
human
fatal
case
mer
report
renal
transplant
recipi
receiv
antireject
therapi
consist
prednison
mycophenol
mofetil
cyclosporin
dosag
serum
drug
level
mycophenol
mofetil
result
lymphocyt
count
report
review
candid
therapi
middl
east
respiratori
syndrom
molecular
perspect
coronavirus
repres
group
rna
virus
largest
rna
genom
date
therefor
develop
resist
mutant
target
drug
remain
concern
viral
replic
repres
potenti
antivir
target
studi
perform
genomewid
sarscov
yeasttwohybrid
interact
screen
human
cdna
librari
identifi
protein
interact
partner
sarscov
nonstructur
protein
protein
bind
immunosuppress
drug
tacrolimu
sinc
interact
protein
investig
whether
inhibit
replic
human
coronavirus
verofm
cell
infect
sarscov
human
coronavirus
treat
studi
found
inhibit
replic
sarscov
nontox
lowmicromolar
concentr
reduct
viral
titer
undetect
level
human
coronavirus
sensit
indic
involv
protein
viral
replic
ppiaseindepend
activ
csa
exert
gainoffunct
result
binari
complex
form
bind
drug
fkbp
base
inhibit
protein
phosphatas
activ
calcineurin
complex
block
cellular
calcineurinnfat
pathway
therebi
interf
tcell
activ
product
analogu
alter
side
chain
modif
